GlassScriptPhysician profile
Geneva Randolph Cason
NPI 1063787422
$1,576.83
in general payments reported to CMS, 2019-2025
16 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $256 · 2023: $473 · 2024: $445 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $165.05 | 2023-2024 | |
| Ars Pharmaceuticals Operations, INC. | $125.01 | 2025 | Neffy |
| Tactile Systems Technology INC | $108.62 | 2023 | Entre Plus, Flexitouch Plus |
| Amgen INC. | $107.70 | 2025 | Evenity |
| Axsome Therapeutics, INC. | $101.76 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $100.01 | 2023 | Gemtesa |
| Gilead Sciences, INC. | $100.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $98.28 | 2023 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $95.76 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $94.55 | 2025 | Aptima |
| Sage Therapeutics, LLC | $94.50 | 2024 | |
| Vertos Medical, INC. | $85.61 | 2022 | |
| Coloplast Corp | $82.61 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $76.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $71.46 | 2023 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $69.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geneva Cason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.